Drug intelligence / Profile preview

neosaxitoxin

Development stage: Phase 1
Lead developer: Cawthron Institute
Modality: Peptides, Small Molecules
Administration: Local Injection, Infiltration, Oral

Overview

Neosaxitoxin is a potent, naturally occurring neurotoxin belonging to the paralytic shellfish toxin group. It is structurally related to saxitoxin and acts as a selective, reversible blocker of voltage-gated sodium channels in neurons. By binding to these channels, neosaxitoxin prevents the influx of sodium ions necessary for action potential propagation, leading to inhibition of neuronal transmission and potentially paralysis. Neosaxitoxin has been investigated as a long-acting local anesthetic due to its ability to block nerve conduction with high specificity. It is currently under clinical investigation for use as a local anesthetic[5][1].

Other names: NEO

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on neosaxitoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on neosaxitoxin.

Explore the full profile